Mounjaro vai ser coisa do passado

Seja membro deste canal e apoie a divulgação científica brasileira: https://www.youtube.com/channel/UCdKJlY5eAoSumIlcOcYxIGg/join #retatutida #mounjaro #ozempic #obesidade Roteiro: Ana Bonassa Produção: Ana Bonassa Edição: Laís Maurelli / Jessica Santana Design da miniatura: Laís Maurelli / Jessica Santana Legendas: Beatriz Pinheiro Busca de conteúdos: www.nv1c.com Referências - Action and therapeutic potential of oxyntomodulin. Mol Metab. 2013. doi: 10.1016/j.molmet.2013.12.001 - Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity. Peptides. 2023. doi: 10.1016/j.peptides.2023.170955 - The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk. Nat Commun. 2024. doi: 10.1038/s41467-024-54080-w - Oxyntomodulin - past, present and future. Peptides. 2025. doi: 10.1016/j.peptides.2025.171393 - Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol. 2012. doi: 10.1530/JOE-12-0368 - Proglucagon-derived peptides: human physiology and therapeutic potential. Physiol Rev. 2026. doi: 10.1152/physrev.00057.2024 - Eli Lilly And Company. [Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial]. Indianapolis: Eli Lilly and Company, 2025. Disponível em: https://investor.lilly.com/node/53536/pdf. Acesso em: 22 jan. 2026. - Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. doi: 10.1056/NEJMoa2301972 - Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025. doi: 10.3390/biom15060796 - The power of three: Retatrutide's role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024. doi: 10.1016/j.ejphar.2024.177095 - Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. doi: 10.1016/S0140-6736(23)01053-X - Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. doi: 10.1038/s41591-024-03018-2 - Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open. 2024. doi: 10.1016/j.metop.2024.100321 - A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol. 2024. doi: 10.1007/s00228-024-03646-0. - Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. doi: 10.1016/S2213-8587(25)00092-0 - Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. doi: 10.1056/NEJMoa2416394 Acompanhe o NV1C nas redes: instagram.com/nuncavi1cientista tiktok.com/@nuncavi1cientista Livro Super-Heróis da Ciência: https://amzn.to/3qZRtxm Apoie este canal! - programa de membros: https://bit.ly/3zwlny9 - chave Pix: [email protected] Quer mandar coisinhas pra gente? Caixa postal: 77785 CEP: 05593-970